Persistent Identifier
|
doi:10.7910/DVN/YBRNXC |
Publication Date
|
2020-02-20 |
Title
| Replication Data for: Dosing of ceftriaxone and metronidazole for children with severe acute malnutrition. |
Author
| Standing, Joseph F.Great Ormond Street Institute of Child Health, University College London, London, UK; Paediatric Infectious Diseases Research Group, Institute for Infection and Immunity, St. George's, University of London, London, UK
Ongas, Martin O.Center for Research in Therapeutic Sciences, Strathmore University, Nairobi, Kenya; KEMRI‐Centre for Clinical Research, Nairobi, Kenya
Ogwang, CarolineKEMRI‐Wellcome Trust Research Programme, Kilifi, Kenya
Kagwanja, NancyKEMRI‐Wellcome Trust Research Programme, Kilifi, Kenya
Murunga, SheilaKEMRI‐Wellcome Trust Research Programme, Kilifi, Kenya
Mwaringa,ShaltonKEMRI‐Wellcome Trust Research Programme, Kilifi, Kenya
Ali, RehemaKEMRI‐Wellcome Trust Research Programme, Kilifi, Kenya
Mturi, NeemaKEMRI‐Wellcome Trust Research Programme, Kilifi, Kenya
Timbwa, MolineKEMRI‐Wellcome Trust Research Programme, Kilifi, Kenya; Mbagathi County Hospital, Nairobi, Kenya
Manyasi, ChristineKEMRI‐Wellcome Trust Research Programme, Kilifi, Kenya; Mbagathi County Hospital, Nairobi, Kenya
Mwalekwa, LauraKEMRI‐Wellcome Trust Research Programme, Kilifi, Kenya; Coast General Hospital, Mombasa, Kenya
Bandika, Victor L.Coast General Hospital, Mombasa, Kenya
Ogutu, BernhardsCenter for Research in Therapeutic Sciences, Strathmore University, Nairobi, Kenya; KEMRI‐Centre for Clinical Research, Nairobi, Kenya
Waichungo, JosephKEMRI‐Wellcome Trust Research Programme, Kilifi, Kenya
Kipper, KarinAnalytical Services International, St George's University of London, London, UK; Institute of Chemistry, University of Tartu, Tartu, Estonia
Berkley, James A.KEMRI‐Wellcome Trust Research Programme, Kilifi, Kenya; The Childhood Acute Illness & Nutrition (CHAIN) Network, Nairobi, Kenya; Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK
FLACSAM‐PK Study Group |
Point of Contact
|
Use email button above to contact.
Berkley, James A. (KEMRI-Wellcome Trust Research programme;) |
Description
| This study forms the initial stage of the First Line Antimicrobials in Complicated Severe Acute Malnutrition (FLACSAM) trial (http://clinicaltrials.gov NCT03174236), which will compare ceftriaxone (±metronidazole) with standard‐of‐care antimicrobials (±metronidazole) in a 2 × 2 factorial design for outcomes including mortality and nutritional recovery. Infants and young children with severe acute malnutrition (SAM) are treated with empiric broad‐spectrum antimicrobials. Parenteral ceftriaxone is currently a second‐line agent for invasive infection. Oral metronidazole principally targets small intestinal bacterial overgrowth. Children with SAM may have altered drug absorption, distribution, metabolism, and elimination. Population pharmacokinetics of ceftriaxone and metronidazole were studied, with the aim of recommending optimal dosing. Eighty‐one patients with SAM (aged 2–45 months) provided 234 postdose pharmacokinetic samples for total ceftriaxone, metronidazole, and hydroxymetronidazole. Ceftriaxone protein binding was also measured in 190 of these samples. A three‐compartment model adequately described free ceftriaxone, with a Michaelis–Menten model for concentration and albumin‐dependent protein binding. A one‐compartment model was used for both metronidazole and hydroxymetronidazole, with only 1% of hydroxymetronidazole predicted to be formed during first‐pass. Simulations showed 80 mg/kg once daily of ceftriaxone and 12.5 mg/kg twice daily of metronidazole were sufficient to reach therapeutic targets. |
Subject
| Medicine, Health and Life Sciences |
Related Publication
| Standing, J.F., Ongas, M.O., Ogwang, C., Kagwanja, N., Murunga, S., Mwaringa, S., Ali, R., Mturi, N., Timbwa, M., Manyasi, C. and Mwalekwa, L., 2018. Dosing of ceftriaxone and metronidazole for children with severe acute malnutrition. Clinical Pharmacology & Therapeutics, 104(6), pp.1165-1174. doi 10.1002%2Fcpt.1078 https://dx.doi.org/10.1002%2Fcpt.1078 |
Notes
| Access to the dataset is restricted. Accompanying documentation is available under open access. For more detailed information beyond the metadata and documentation provided, there is a process of managed access requiring submission of a request form for consideration by our Data Governance Committee [dgc@kemri-wellcome.org). Click to download Data Request Form |
Depositor
| Berkley, James A. |
Deposit Date
| 2020-02-17 |
Data Type
| Clinical Trial |